A Systems-Based Framework for Targeting Cancer Through Metabolism, Oxygenation, and Immune Modulation

Executive Summary

Cancer metabolism has traditionally been framed around glucose dependence (Warburg effect) and glutamine utilization. However, emerging evidence demonstrates that many tumors exhibit significant metabolic flexibility, including the capacity to utilize fatty acids through fatty acid oxidation (FAO), particularly under therapeutic pressure.This white paper presents a systems-based metabolic oncology framework that integrates:

• Cyclical metabolic stress (dietary intervention)
• Oxygen modulation (HBOT)
• Oxidative stress amplification (IV Vitamin C)
• Immune activation (exercise / IL-15)

The objective is not simply to restrict a single fuel, but to limit tumor adaptability by creating dynamic and unfavorable metabolic environments.

1. Background: Cancer as a Metabolic Disease

Cancer cells exhibit altered energy metabolism characterized by:

• Increased glycolysis (Warburg effect)
• Elevated glutamine metabolism
• Mitochondrial dysfunction or reprogramming
• Adaptation to hypoxic environments

However, growing evidence indicates that:

Cancer is not metabolically rigid, but highly adaptive.

Tumors can shift between:

• Glucose metabolism
• Glutamine metabolism
• Fatty acid oxidation (FAO)

This metabolic plasticity is a key driver of resistance.

2. The Limitation of Single-Pathway Targeting

Traditional approaches focus on inhibiting:

• Glycolysis
• Glutaminolysis

However, tumors frequently compensate by:

• Increasing fatty acid uptake and oxidation
• Enhancing mitochondrial efficiency
• Utilizing alternative substrates (lactate, ketones)

This suggests that:

Targeting a single metabolic pathway is insufficient.

3. Core Concept: Cyclical Metabolic Stress

This framework introduces metabolic cycling as a therapeutic strategy. Each cycle includes:

1. Baseline phase (controlled fuel availability)
2. Stress phase (multi-pathway metabolic pressure)
3. Recovery phase (physiological resilience)

This approach aims to:

• Prevent metabolic adaptation
• Increase tumor vulnerability
• Preserve patient safety

4. Core Interventions

4.1 Fasting Mimicking Diet (FMD)

The FMD induces systemic metabolic reprogramming through:

• Reduced glucose
• Reduced insulin and IGF-1
• Reduced mTOR signaling
• Reduced amino acid availability

This results in:

• Decreased growth signaling
• Increased cellular stress
• Differential stress resistance

4.2 Hyperbaric Oxygen Therapy (HBOT)

HBOT increases tissue oxygenation and induces:

• Increased ROS production
• Reduced tumor hypoxia
• Increased mitochondrial pressure

Cancer cells, already under oxidative stress, are particularly vulnerable.

4.3 Intravenous Vitamin C

At pharmacological doses, IV Vitamin C acts as a pro-oxidant by generating hydrogen peroxide. Effects include:

• Increased extracellular ROS
• Selective toxicity to cancer cells
• Synergy with oxygen-based therapies

4.4 Exercise and Immune Activation

Exercise stimulates IL-15 and enhances:

• Natural killer (NK) cell activity
• Immune surveillance
• Systemic resilience

When combined with oxygen (EWOT), these effects may be enhanced.

5. Standard Protocol (General Tumor Types)

28-Day Cycle

Days 1–16 (Baseline Phase):

• Low glucose diet
• Moderate protein
• Controlled fat intake
• Light to moderate activity
• EWOT: 2–3 sessions/week

Days 17–21 (Stress Phase):

• FMD protocol
• HBOT: daily sessions
• IV Vitamin C: 2–3 sessions
• Polyphenols and metabolic stressors
• No EWOT

Days 22–28 (Recovery Phase):

• Gradual refeeding
• Light activity
• EWOT: optional, low intensity

6. FAO-Adaptive Tumors

Certain cancers demonstrate increased reliance on fatty acid metabolism:

• Prostate cancer
• Triple-negative breast cancer
• Ovarian cancer
• Acute myeloid leukemia (AML)
• Melanoma
• Adaptive glioblastoma

These tumors exhibit:

• Increased fatty acid uptake (CD36)
• Increased FA transport (FABP)
• Increased mitochondrial oxidation (CPT1A)

7. Adjusted Strategy for FAO Tumors

Key principles:

• Avoid prolonged ketosis
• Control fat intake
• Maintain low glucose
• Emphasize metabolic cycling

Protocol Adjustments

Baseline Phase:

• Low glucose
• Moderate protein
• Controlled fat
• Light activity

Stress Phase:

• FMD
• HBOT
• IV Vitamin C
• No EWOT

Recovery Phase:

• Controlled refeeding

EWOT is minimized or avoided due to its stimulation of fatty acid oxidation.

8. Integrated Model

The framework operates across four axes:

1. Fuel restriction (FMD)
2. Oxygen modulation (HBOT)
3. Oxidative stress (IV Vitamin C)
4. Immune activation (exercise)

The goal is to create a metabolic environment where:

• No dominant fuel is available
• Oxidative stress is increased
• Adaptation is limited

9. Clinical Integration with Standard Oncology Treatments

This protocol is best implemented as an adjunct therapy, designed to enhance the effectiveness of chemotherapy, radiotherapy, and immunotherapy while improving patient resilience.Timing and coordination are critical.

9.1 Integration with Chemotherapy

Objective:

• Increase tumor sensitivity
• Reduce toxicity in healthy cells

Recommended approach:

• Day -2 to Day 0 (before chemotherapy):
  • Begin FMD (2–3 days before infusion)
  • Maintain hydration and electrolyte balance
• Day 0 (chemotherapy day):
  • Continue FMD
  • Optional: IV Vitamin C (timed several hours before or after chemo, depending on protocol)
• Day +1 to +2 (after chemotherapy):
  • Continue FMD (total 4–5 days)
  • Introduce HBOT (1 session per day if tolerated)
• Post-FMD (recovery phase):
  • Gradual refeeding
  • Light activity
  • Resume EWOT only after recovery (2–3 days later)

Cycle repeats with each chemotherapy session.

9.2 Integration with Radiotherapy

Objective:

• Enhance radiosensitivity via oxygen and ROS

Recommended approach:

• Throughout radiotherapy course:
  • HBOT: ideally performed immediately before or within a few hours prior to radiation sessions
  • Frequency: 3–5 sessions per week
• FMD cycles:
  • Apply 5-day FMD cycles every 3–4 weeks during treatment
  • Align FMD with peak radiation periods if possible
• IV Vitamin C:
  • 2–3 sessions per week
  • Preferably on non-radiation days or several hours apart
• EWOT:
  • Only during non-FMD periods
  • 2x per week, moderate intensity

9.3 Integration with Immunotherapy

Objective:

• Support immune activation without suppressing immune function

Recommended approach:

• FMD:
  • Shorter or less frequent cycles (every 4–6 weeks)
  • Avoid excessive or prolonged fasting
• HBOT:
  • 2–3 sessions per week
  • Avoid excessive oxidative stress during peak immune activation
• IV Vitamin C:
  • 1–2 sessions per week
  • Monitor tolerance and inflammatory markers
• EWOT / Exercise:
  • Central component
  • 2–3 sessions per week
  • Focus on immune stimulation (IL-15, NK cells)

9.4 Standalone or Maintenance Use

This protocol may be used independently in specific contexts:

• Maintenance after standard treatment
• Prevention of recurrence
• Patients unable or unwilling to undergo conventional therapy

In these cases, apply the standard 28-day metabolic cycle with periodic reassessment.

10. Clinical Considerations

• Requires medical supervision
• Must be personalized
• Should complement standard oncology care
• Requires monitoring (weight, metabolic markers, tolerance)

11. Conclusion

Metabolic Oncology 2.0 represents a shift from static interventions to dynamic metabolic control. Rather than targeting cancer with a single mechanism, this approach:

• Limits metabolic flexibility
• Increases oxidative pressure
• Supports immune function

The most effective therapy is not the most aggressive, but the one cancer cannot adapt to.

References

Longo VD, Mattson MP. Cell Metabolism. 2014 Brandhorst S et al. Cell Metabolism. 2015 Seyfried TN. Cancer as a Metabolic Disease. 2012 Seyfried TN et al. Nutrition & Metabolism. 2020 Poff AM et al. PLoS One. 2013 Wallace DC. Nature Reviews Cancer. 2012 Nieman KM et al. Nature Medicine. 2011 Tabe Y et al. Frontiers in Oncology. 2020 Carracedo A et al. Nature Reviews Cancer. 2013 Kant S et al. Cancer Research. 2020 Chen Q et al. PNAS. 2005